RetaMaps

Weill Cornell Endocrinology — David J. Brillon, MD

NewYork-Presbyterian / Weill Cornell (525 E 68th St) · 525 E 68th St # F-2020 · New York, NY 10065

3.0· 22 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Weill Cornell Medicine / NewYork-Presbyterian endocrinology is an academic diabetes and metabolism program in Manhattan. The official VIVO profile lists David J. Brillon as Professor Emeritus of Clinical Medicine (since 2016) with a long research record in type 1 and type 2 diabetes. He does not appear on a current public clinical faculty roster, so active patient scheduling should be verified. This is academic endocrinology/diabetes, not a cash GLP-1 clinic; official pages do not name GLP-1 brands.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visits—
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice website—

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 3.0
Google rating · 22 reviews
6
reviews in the past year (avg ★ 3.7)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-23. Read the reviews themselves on the practice's Google listing.

Clinicians

  • David J. Brillon, MD

Nearby providers in New York City

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs